Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accounts Payables (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Accounts Payables for 7 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 36.77% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 36.77% increase, with the full-year FY2025 number at $1.6 million, up 36.77% from a year prior.
  • Accounts Payables was $1.6 million for Q4 2025 at Fulcrum Therapeutics, down from $2.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $6.0 million in Q1 2022 to a low of $1.2 million in Q4 2024.
  • A 5-year average of $3.5 million and a median of $3.7 million in 2021 define the central range for Accounts Payables.
  • Biggest YoY gain for Accounts Payables was 36.77% in 2025; the steepest drop was 60.93% in 2025.
  • Fulcrum Therapeutics' Accounts Payables stood at $4.8 million in 2021, then decreased by 24.02% to $3.6 million in 2022, then decreased by 24.22% to $2.8 million in 2023, then tumbled by 57.78% to $1.2 million in 2024, then surged by 36.77% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Accounts Payables are $1.6 million (Q4 2025), $2.9 million (Q3 2025), and $1.8 million (Q2 2025).